ID   CP4V2_HUMAN             Reviewed;         525 AA.
AC   Q6ZWL3; B7U6W2; Q6ZTM4;
DT   02-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   10-MAY-2017, entry version 138.
DE   RecName: Full=Cytochrome P450 4V2;
DE            EC=1.14.13.-;
DE   AltName: Full=Docosahexaenoic acid omega-hydroxylase CYP4V2 {ECO:0000305};
DE            EC=1.14.13.199 {ECO:0000269|PubMed:22772592};
GN   Name=CYP4V2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS BCD ARG-44; SER-61; ASP-79; THR-111; VAL-123; LYS-259;
RP   PRO-331; PRO-341 AND HIS-508.
RC   TISSUE=Retina;
RX   PubMed=15042513; DOI=10.1086/383228;
RA   Li A., Jiao X., Munier F.L., Schorderet D.F., Yao W., Iwata F.,
RA   Hayakawa M., Kanai A., Shy Chen M., Alan Lewis R., Heckenlively J.,
RA   Weleber R.G., Traboulsi E.I., Zhang Q., Xiao X., Kaiser-Kupfer M.,
RA   Sergeev Y.V., Hejtmancik J.F.;
RT   "Bietti crystalline corneoretinal dystrophy is caused by mutations in
RT   the novel gene CYP4V2.";
RL   Am. J. Hum. Genet. 74:817-826(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LYS-259.
RC   TISSUE=Kidney, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-22; ASN-213;
RP   LYS-275; ILE-372 AND GLN-443.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LYS-259.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE
RP   SPECIFICITY, AND ENZYME REGULATION.
RX   PubMed=19661213; DOI=10.1124/dmd.109.028530;
RA   Nakano M., Kelly E.J., Rettie A.E.;
RT   "Expression and characterization of CYP4V2 as a fatty acid omega-
RT   hydroxylase.";
RL   Drug Metab. Dispos. 37:2119-2122(2009).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND CHARACTERIZATION OF VARIANT BCD PRO-331.
RX   PubMed=22772592; DOI=10.1124/mol.112.080085;
RA   Nakano M., Kelly E.J., Wiek C., Hanenberg H., Rettie A.E.;
RT   "CYP4V2 in Bietti's crystalline dystrophy: ocular localization,
RT   metabolism of omega-3-polyunsaturated fatty acids, and functional
RT   deficit of the p.H331P variant.";
RL   Mol. Pharmacol. 82:679-686(2012).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Omega-hydroxylase that oxidizes medium-chain saturated
CC       fatty acids and polyunsaturated omega-3 fatty acids, and which
CC       plays a role in fatty acid and steroid metabolism in the eye
CC       (PubMed:19661213, PubMed:22772592). Catalyzes the omega-
CC       hydroxylation of medium-chain saturated fatty acids such as
CC       laurate, myristate and palmitate in an NADPH-dependent pathway.
CC       The substrate specificity is higher for myristate > laurate >
CC       palmitate (C14>C16>C12) (PubMed:19661213). Acts as a
CC       polyunsaturated omega-3 fatty acids hydroxylase by mediating
CC       oxidation of docosahexaenoate (DHA) to 22-hydroxydocosahexaenoate
CC       (PubMed:22772592). Also produces some 21-hydroxydocosahexaenoate.
CC       Also converts eicosapentaenoate (EPA) to 20-
CC       hydroxyeicosapentaenoate (20-OH-EPA) (PubMed:22772592).
CC       {ECO:0000269|PubMed:19661213, ECO:0000269|PubMed:22772592}.
CC   -!- CATALYTIC ACTIVITY: Docosahexaenoate + NADPH + O(2) = 22-
CC       hydroxydocosahexaenoate + NADP(+) + H(2)O.
CC       {ECO:0000269|PubMed:22772592}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:P51869};
CC   -!- ENZYME REGULATION: Inhibited by N-hydroxy-N'-(4-n-butyl-2-
CC       methylphenyl formamidine)(HET0016) with an IC(50) of 38 nM.
CC       {ECO:0000269|PubMed:19661213}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=65 uM for myristic acid {ECO:0000269|PubMed:19661213};
CC         KM=140 uM for lauric acid {ECO:0000269|PubMed:19661213};
CC         KM=430 uM for palmitic acid {ECO:0000269|PubMed:19661213};
CC         Note=Vmax is the nearly the same for myristic acid and for
CC         lauric acid and reduced about 30% for palmitic acid.
CC         {ECO:0000269|PubMed:19661213};
CC   -!- PATHWAY: Lipid metabolism. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:22772592}; Single-pass membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6ZWL3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6ZWL3-2; Sequence=VSP_014918;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Broadly expressed. Detected in heart, brain,
CC       placenta, lung, liver, skeletal muscle, kidney, pancreas, retina,
CC       retinal pigment epithelium (RPE) and lymphocytes.
CC       {ECO:0000269|PubMed:15042513, ECO:0000269|PubMed:22772592}.
CC   -!- DISEASE: Bietti crystalline corneoretinal dystrophy (BCD)
CC       [MIM:210370]: An autosomal recessive ocular disease characterized
CC       by retinal degeneration and marginal corneal dystrophy. Typical
CC       features include multiple glistening intraretinal crystals
CC       scattered over the fundus, a characteristic degeneration of the
CC       retina, and sclerosis of the choroidal vessels, ultimately
CC       resulting in progressive night blindness and constriction of the
CC       visual field. Most patients have similar crystals at the
CC       corneoscleral limbus. Patients develop decreased vision,
CC       nyctalopia, and paracentral scotomata between the 2nd and 4th
CC       decade of life. Later, they develop peripheral visual field loss
CC       and marked visual impairment, usually progressing to legal
CC       blindness by the 5th or 6th decade of life.
CC       {ECO:0000269|PubMed:15042513, ECO:0000269|PubMed:22772592}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp4v2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY422002; AAR31180.1; -; mRNA.
DR   EMBL; AK122600; BAC85487.1; -; mRNA.
DR   EMBL; AK126473; BAC86562.1; -; mRNA.
DR   EMBL; FJ440682; ACK44069.1; -; Genomic_DNA.
DR   EMBL; AC110771; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC060857; AAH60857.1; -; mRNA.
DR   CCDS; CCDS34119.1; -. [Q6ZWL3-1]
DR   RefSeq; NP_997235.3; NM_207352.3. [Q6ZWL3-1]
DR   UniGene; Hs.587231; -.
DR   ProteinModelPortal; Q6ZWL3; -.
DR   SMR; Q6ZWL3; -.
DR   BioGrid; 130113; 5.
DR   IntAct; Q6ZWL3; 1.
DR   STRING; 9606.ENSP00000368079; -.
DR   SwissLipids; SLP:000000542; -.
DR   iPTMnet; Q6ZWL3; -.
DR   PhosphoSitePlus; Q6ZWL3; -.
DR   BioMuta; CYP4V2; -.
DR   DMDM; 296434466; -.
DR   MaxQB; Q6ZWL3; -.
DR   PaxDb; Q6ZWL3; -.
DR   PeptideAtlas; Q6ZWL3; -.
DR   PRIDE; Q6ZWL3; -.
DR   Ensembl; ENST00000378802; ENSP00000368079; ENSG00000145476. [Q6ZWL3-1]
DR   GeneID; 285440; -.
DR   KEGG; hsa:285440; -.
DR   UCSC; uc003iyw.5; human. [Q6ZWL3-1]
DR   CTD; 285440; -.
DR   DisGeNET; 285440; -.
DR   GeneCards; CYP4V2; -.
DR   GeneReviews; CYP4V2; -.
DR   H-InvDB; HIX0004688; -.
DR   HGNC; HGNC:23198; CYP4V2.
DR   HPA; HPA029122; -.
DR   MalaCards; CYP4V2; -.
DR   MIM; 210370; phenotype.
DR   MIM; 608614; gene.
DR   neXtProt; NX_Q6ZWL3; -.
DR   OpenTargets; ENSG00000145476; -.
DR   Orphanet; 41751; Bietti crystalline dystrophy.
DR   PharmGKB; PA134912942; -.
DR   eggNOG; KOG0157; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118816; -.
DR   HOGENOM; HOG000233834; -.
DR   HOVERGEN; HBG000182; -.
DR   InParanoid; Q6ZWL3; -.
DR   KO; K07427; -.
DR   OMA; NEMNANE; -.
DR   OrthoDB; EOG091G06KN; -.
DR   PhylomeDB; Q6ZWL3; -.
DR   TreeFam; TF105088; -.
DR   BRENDA; 1.14.13.199; 2681.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-2453902; The canonical retinoid cycle in rods (twilight vision).
DR   GeneWiki; CYP4V2; -.
DR   GenomeRNAi; 285440; -.
DR   PRO; PR:Q6ZWL3; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000145476; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; TAS:Reactome.
DR   GO; GO:0016705; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; IEA:InterPro.
DR   GO; GO:0010430; P:fatty acid omega-oxidation; IDA:UniProtKB.
DR   GO; GO:0050896; P:response to stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Corneal dystrophy;
KW   Disease mutation; Endoplasmic reticulum; Heme; Iron; Lipid metabolism;
KW   Membrane; Metal-binding; Monooxygenase; NADP; Oxidoreductase;
KW   Polymorphism; Reference proteome; Sensory transduction; Transmembrane;
KW   Transmembrane helix; Vision.
FT   CHAIN         1    525       Cytochrome P450 4V2.
FT                                /FTId=PRO_0000051859.
FT   TRANSMEM     13     33       Helical. {ECO:0000255}.
FT   METAL       467    467       Iron (heme axial ligand).
FT                                {ECO:0000250|UniProtKB:P51869}.
FT   BINDING     329    329       Heme (covalent; via 1 link).
FT                                {ECO:0000250|UniProtKB:P51869}.
FT   VAR_SEQ      42     63       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_014918.
FT   VARIANT      22     22       L -> V (in dbSNP:rs1055138).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_038606.
FT   VARIANT      44     44       W -> R (in BCD; dbSNP:rs119103282).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023084.
FT   VARIANT      61     61       G -> S (in BCD; dbSNP:rs119103285).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023085.
FT   VARIANT      79     79       E -> D (in BCD; dbSNP:rs199476185).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023086.
FT   VARIANT     111    111       I -> T (in BCD; dbSNP:rs119103283).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023087.
FT   VARIANT     123    123       M -> V (in BCD; dbSNP:rs149684063).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023088.
FT   VARIANT     213    213       S -> N (in dbSNP:rs34331648).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_038607.
FT   VARIANT     259    259       Q -> K (in dbSNP:rs13146272).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15042513,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_033821.
FT   VARIANT     275    275       E -> K (in dbSNP:rs34745240).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_055379.
FT   VARIANT     331    331       H -> P (in BCD; impaired omega
FT                                hydroxylase activity; dbSNP:rs199476197).
FT                                {ECO:0000269|PubMed:15042513,
FT                                ECO:0000269|PubMed:22772592}.
FT                                /FTId=VAR_023089.
FT   VARIANT     341    341       S -> P (in BCD; dbSNP:rs199476199).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023090.
FT   VARIANT     372    372       V -> I (in dbSNP:rs61755911).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_055380.
FT   VARIANT     443    443       R -> Q (in dbSNP:rs72646291).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_055381.
FT   VARIANT     508    508       R -> H (in BCD; dbSNP:rs119103284).
FT                                {ECO:0000269|PubMed:15042513}.
FT                                /FTId=VAR_023091.
SQ   SEQUENCE   525 AA;  60724 MW;  A26F0A517C9569AD CRC64;
     MAGLWLGLVW QKLLLWGAAS ALSLAGASLV LSLLQRVASY ARKWQQMRPI PTVARAYPLV
     GHALLMKPDG REFFQQIIEY TEEYRHMPLL KLWVGPVPMV ALYNAENVEV ILTSSKQIDK
     SSMYKFLEPW LGLGLLTSTG NKWRSRRKML TPTFHFTILE DFLDIMNEQA NILVKKLEKH
     INQEAFNCFF YITLCALDII CETAMGKNIG AQSNDDSEYV RAVYRMSEMI FRRIKMPWLW
     LDLWYLMFKE GWEHKKSLQI LHTFTNSVIA ERANEMNANE DCRGDGRGSA PSKNKRRAFL
     DLLLSVTDDE GNRLSHEDIR EEVDTFMFEG HDTTAAAINW SLYLLGSNPE VQKKVDHELD
     DVFGKSDRPA TVEDLKKLRY LECVIKETLR LFPSVPLFAR SVSEDCEVAG YRVLKGTEAV
     IIPYALHRDP RYFPNPEEFQ PERFFPENAQ GRHPYAYVPF SAGPRNCIGQ KFAVMEEKTI
     LSCILRHFWI ESNQKREELG LEGQLILRPS NGIWIKLKRR NADER
//
